WO2015062596A1 - Hair treatment agent containing l-carnitine or an l-carnitine derivative and an oligopeptide containing the sequence glu-glu-glu - Google Patents

Abstract

The present invention relates to the use of a hair treatment agent containing at least one compound selected from L-carnitine and/or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and L-carnitine tartrate, and at least one oligopeptide which comprises at least one amino acid sequence Glu-Glu-Glu, wherein the amino group may be in free or protonated form and the carboxyl groups may be in free or deprotonated form, for promoting or increasing hair growth and/or for reducing hair loss and/or for activating the hair root cells and/or for activating hair follicles and/or for thickening the hair.

Description

 HAIR TREATMENT CONTAINING L-CARNITINE

 OR AN L-CARNITINE DERIVATIVE AND AN OLIGOPEPTIDE

 CONTAINING THE SEQUENCE GLU-GLU-GLU

The invention relates to the use of hair treatment compositions with certain ingredients to promote or enhance the hair growth and / or reduce hair loss and / or activation of the hair root cells and / or activation of hair follicles and / or thickening of the hair.

 On average, between 70 and 100 hairs per day are lost by humans, but as the hair roots usually remain in the scalp and regrow, hair loss is constantly replaced and hair loss is not visible. With hair loss is thus meant the permanent hair loss, in which the failed hair again very late, usually getting thinner or not at all, regrow.

Hair loss is a widespread cosmetic problem for both men and women and can be psychologically stressful. In men, it is mainly characterized by a receding hairline on the forehead and decreasing hair density in the vertex area. In women, there is usually a general reduction in hair density over the entire head.

 Hair loss occurs when, due to various causes, the so-called hair cycle is disturbed. In the hair cycle, the hair usually regenerates itself. After a growth phase (anagen), in which about 80-90% of the hair is and takes between 2 and 6 years, follows the so-called regression phase (catagen, about 3-6 weeks), in the metabolic processes in the hair root be reduced. About 2% of the hair is usually in this resting phase. During the hair cycle, this phase forms the transition between the anagen phase and the telogen phase.

The Telogen phase, which is constantly about 10-20% of the hair, is the resting phase (duration about 3 months), after which the hair fails and a new growth phase begins in this follicle. With increased hair loss, it can be e.g. An increase in telogen, and a shortening of the anagen phase, so that the proportion of failing hair increases without being replaced by new, beginning the growth phase.

At present, there are hardly any cosmetic preparations on the market which significantly improve hair growth and structure or prevent hair loss.

HGF and KGF are important growth factors that are released by the dermal papilla to control the proliferation of hair keratinocytes. In a potentially growth-promoting and hair-strengthening substance, these parameters should be influenced in any case. The treatment of thin hair is a consumer need. However, conventional structurally improving and smoothing molecules can complain the hair and lead to a "over-care"

 Improving the hair structure from the root, the production site for hair-building keratins, is an efficient and sustainable method of treating thin hair.

 Maintaining or rejuvenating the youthfulness of hair through suitable formulations of active ingredients is a challenge for cosmetic research.

The object of the present invention was to provide agents that promote or enhance hair growth and reduce hair loss and activate the hair root cells and / or hair follicles. Thickening the hair was another object of the present invention.

 This object is achieved according to the invention by the use of agents which contain at least one compound selected from L-carnitine and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and L. Carnitine tartrate and at least one oligopetide having at least one amino acid sequence Glu-Glu-Glu

where the amino group is free or protonated and the carboxy groups may be free or deprotonated.

 The present invention therefore relates to the use of a hair treatment composition containing

 a) at least one compound selected from L-carnitine and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and L-carnitine tartrate;

b) at least one oligopetide having at least one amino acid sequence Glu-Glu-Glu

 wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated

 to

 Promotion or enhancement of hair growth and / or

 Reduction of hair loss and / or

 Activation of hair root cells and / or

 Activation of hair follicles and / or

 Thickening of the hair.

Hair treatment compositions in the context of the present invention are, for example, hair shampoos, hair conditioners, conditioning shampoos, hairsprays, hair conditioners, hair conditioners, hair wraps, hair tonics, perming solutions, hair dye shampoos, hair dyes, hair fixatives, hair dressings, hairstyling preparations, hair lotions, mousses, hair gels , Hair waxes or their combinations. In view of the fact that men often shy away from the use of several different agents and / or several application steps, means according to the invention are preferably agents which the man applies anyway. Preferred agents according to the invention are therefore shampoos, conditioners or hair tonics.

 The hair treatment agents used according to the invention are capable of positively influencing hair growth by repressing or reducing specific inhibiting hair-specific genes. The repression or reduction of the inhibiting genes, causes the hair root can be reactivated. In addition, the hair structure is already influenced on the hair roots, so that the hair can grow strong and healthy and thicker.

 Furthermore, it has been found that the hair is positively influenced in its growth and metabolism by the application of said agents.

The penetration of active substances into the follicle is usually more difficult since the corresponding target, the dermal papilla and the ORS keratinocytes, are embedded approximately 2 mm deep in the scalp. The use of liposomes increases the penetration of one Active ingredient, so that hair treatment agents that contain the above-mentioned drugs liposomal encapsulated, work very well. Surprisingly, it has been found that these compositions show sufficient penetration to the site of action even if the use of liposomes is not possible for formulation-technical reasons.

 The hair treatment compositions used according to the invention contain as essential ingredient at least one compound selected from L-carnitine and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl L-carnitine and L-carnitine tartrate ,

 The agents used according to the invention may contain L-carnitine and / or an L-carnitine derivative or else a plurality of different L-carnitine derivatives.

L-carnitine or L-carnitine derivatives are contained in the compositions according to the invention preferably in amounts of 0.001 to 10 wt .-%, based on the total preparation. Levels of 0.1 to 10 wt .-% are particularly preferred, amounts of 0.1 to 5 wt .-% are particularly preferred, and amounts of 1 to 3 wt .-% are very particularly preferred.

 Particularly preferred hair treatment agents used according to the invention are characterized in that they are 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt % and in particular 0.1 to 3 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl Carnitine and in particular L-carnitine tartrate included.

 Hair treatment agents preferably used according to the invention contain from 0.0001 to 10% by weight of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl- Carnitine and in particular L-carnitine tartrate.

 Preferred uses of the invention are summarized in that the hair treatment agent - based on its weight - 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4% by weight and in particular 0.1 to 3% by weight of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine Citrate, lauroyl-L-carnitine and especially L-carnitine tartrate.

The hair treatment compositions used according to the invention contain as further essential ingredient at least one oligopeptide containing at least one amino acid sequence Glu-Glu-Glu

wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated.

 Preferred uses according to the invention are characterized in that the hair treatment composition contains, based on its weight, 0.0001 to 10% by weight of at least one oligopeptide containing at least one amino acid sequence Glu-Glu-Glu

wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated

 In this formula as well as in the formulas below, the parenthetized hydrogen atom of the amino group, as well as the parenthetical group of the acid function, means that the groups concerned may be present as such (then an oligopeptide having the relevant number of amino acids as shown (in the above) Formula 3) or that the amino acid sequence is present in an oligopeptide, which also comprises other amino acids - depending on where the other amino acid (s) is / are bound, the parenthetical components of the above formula by the / the other Replaced amino acid residue (s).

These preferred hair treatment compositions according to the invention contain - based on their weight - 0.0001 to 10 wt .-% of at least one oligopeptide having at least one amino acid residue Glu-Glu-Glu, ie at least three consecutive glutamic acids. Oligopeptides in the sense of the present application are acid amide-like linked condensation products of amino acids which comprise at least 3 and at most 25 amino acids by peptide bonds

 In preferred hair treatment compositions used according to the invention, the oligopeptide comprises 5 to 15 amino acids, preferably 6 to 13 amino acids, particularly preferably 7 to 12 amino acids and in particular 8, 9 or 10 amino acids.

 Depending on whether further amino acids are bound to the sequence Glu-Glu-Glu and depending on the nature of these amino acids, the molecular weight of the oligopeptide contained in the agents used according to the invention may vary. Preferred hair treatment agents used according to the invention are characterized in that the oligopeptide has a molecular weight of from 650 to 3000 Da, preferably from 750 to 2500 Da, particularly preferably from 850 to 2000 Da and in particular from 1000 to 1600 Da.

 In summary, preferred uses are characterized in that the oligopeptide comprises 5 to 15 amino acids, preferably 6 to 13 amino acids, more preferably 7 to 12 amino acids and especially 8, 9 or 10 amino acids and a molecular weight of 650 to 3000 Da, preferably 750 to 2500 Since, more preferably from 850 to 2000 Da and in particular from 1000 to 1600 Da has.

As can be seen from the preferred number of amino acids in the oligopeptides and the preferred molecular weight range, it is preferred to use oligopeptides which do not consist solely of the three glutamic acids but have further amino acids bound to this sequence. These other amino acids are preferably selected from certain amino acids, while certain other representatives are less preferred in the present invention.

 Thus it is preferred if the oligopeptides used in the agents used according to the invention contain no methionine.

 It is further preferred if the oligopeptides used in the agents used according to the invention do not contain cysteine and / or cystine.

 It is further preferred if the oligopeptides used in the agents used according to the invention contain no aspartic acid and / or asparagine.

 It is further preferred if the oligopeptides used in the agents used according to the invention do not contain serine and / or threonine.

 In contrast, it is preferred if the oligopeptides used in the agents used according to the invention contain tyrosine.

 It is further preferred if the oligopeptides used in the agents according to the invention contain leucine.

It is further preferred if the oligopeptides used in the agents used according to the invention contain isoleucine. It is further preferred if the oligopeptides used in the agents used according to the invention contain arginine.

 It is further preferred if the oligopeptides used in the agents according to the invention contain valine.

 Particularly preferred oligopeptides or amino acid sequences contained in the preferred oligopeptides are described below:

 A particularly preferred oligopeptide additionally contains tyrosine, which is preferably linked via its acid function to the Glu-Glu-Glu sequence. Hair treatment compositions which are preferred according to the invention are therefore characterized in that the oligopeptide contained in them has at least one amino acid sequence Tyr-Glu-Glu-Glu, where the amino group may be free or protonated and the carboxy groups may be free or deprotonated. Another particularly preferred oligopeptide additionally contains isoleucine, which is preferably linked to the Glu-Glu-Glu sequence via its amino function. Hair treatment agents which are preferred according to the invention are therefore characterized in that the oligopeptide contained in them has at least one amino acid sequence Glu-Glu-Glu-Ile, wherein the amino group can be free or protonated and the carboxy groups can be free or deprotonated.

 Oligopeptides which have both the abovementioned amino acids (tyrosine and isoleucine) are preferred according to the invention. Particular preference is given to uses according to the invention in which the oligopeptide contained in the hair treatment agent has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile, where the amino group may be free or protonated and the carboxy groups may be free or deprotonated.

Further preferred oligopeptides additionally contain arginine, which is preferably bound to isoleucine

 Particular preference is given to uses according to the invention in which the oligopeptide contained in the hair treatment agent has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg, wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

 Still further preferred oligopeptides additionally contain valine, which is preferably bound to the arginine. Further preferred uses according to the invention are therefore characterized in that the oligopeptide contained in the hair treatment agent has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val, wherein the amino groups are free or protonated and the carboxy groups are free or deprotonated can.

Still further preferred oligopeptides additionally contain leucine, which is preferably bound to the valine. Further preferred uses according to the invention are therefore characterized in that the oligopeptide contained in the hair treatment agent has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu, wherein the amino groups are free or protonated and the carboxy groups may be present freely or deprotonated.

 Particularly preferred oligopeptides additionally contain leucine, which is preferably bound to the tyrosine. Further preferred uses according to the invention are therefore characterized in that the oligopeptide contained in the hair treatment agent has at least one amino acid sequence Leu-Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu, wherein the amino groups are free or protonated and the carboxy groups may be free or deprotonated.

 With very particular preference, agents used according to the invention comprise at least two oligopeptides which satisfy the abovementioned criteria but which differ from one another. For example, it is preferable to use hair treatment agents containing at least two mutually different oligopetides A and B both containing the amino acid sequence Glu-Glu-Glu.

 Such mutually different oligopeptides A and B correspond to each other in that they carry three consecutive Glu amino acids in their amino acid sequence, but have differences in the upstream or downstream amino acids. Preference is given to mutually different peptides with partial agreement, which may well be greater than in the above-mentioned three amino acids.

 Thus, further preferred uses are characterized in that the hair treatment composition contains at least two mutually different oligopetides A and B, both of which contain the amino acid sequence Glu-Glu-Glu-Ile.

Also preferred are uses of hair treatment compositions containing at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu.

 Still further preferred uses are characterized in that

Hair treatment agent contains at least two mutually different oligopeptides A and B, both of which contain the amino acid sequence Glu-Glu-Glu-Ile-Arg.

 Also still further preferred uses are characterized in that the

Hair treatment agent contains at least two mutually different oligopeptides A and B, both of which contain the amino acid sequence Tyr-Glu-Glu-Glu-Ile.

 Preferred uses according to the invention are therefore characterized in that

Oligopeptid has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile, wherein the

Amino group is free or protonated and the carboxy groups may be free or deprotonated.

Very particularly preferred uses are characterized in that the hair treatment agent at least two mutually different oligopeptides A and B. Both contain the amino acid sequence Glu-Glu-Glu-Ile-Arg.

Also very particularly preferred uses are characterized in that the hair treatment agent contains at least two mutually different oligopeptides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg.

Preferably, there is an even greater structural match in the oligopeptides. Thus, uses in which the hair treatment compositions contain at least two distinct oligopetides A and B both containing the amino acid sequence Glu-Glu-Glu-Ile-Arg-Val are further preferred embodiments of the present invention. Also preferred embodiments are uses in which the hair treatment agents contain at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val.

Still further preferred uses of the invention are characterized in that the hair treatment agents contain at least two mutually different oligopetides A and B, both containing the amino acid sequence Glu-Glu-Glu-Ile-Arg-Val-Leu.

Still further preferred uses of the invention are characterized in that the hair treatment agents contain at least two mutually different oligopetides A and B, both containing the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu.

 Preferred uses according to the invention are therefore characterized in that the oligopeptide has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu, where the amino groups may be free or protonated and the carboxy groups may be free or deprotonated,

 Particularly preferred uses according to the invention are characterized in that the hair treatment compositions contain at least two mutually different oligopetides A and B, the oligopeptide A having the amino acid sequence Leu-Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu, where the amino- Groups may be free or protonated and the carboxy groups may be free or deprotonated

and the oligopeptide B has the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu, wherein the amino groups may be free or protonated and the carboxy groups may be free or deprotonated.

 In most preferred uses of this latter embodiment, the hair treatment compositions contain, based on the weight of the composition, from 0.00001 to 1% by weight of oligopeptide A and from 0.00001 to 1% by weight of oligopeptide B.

 In further preferred uses of this latter embodiment, the hair treatment compositions contain, based on the weight of the composition, from 0.00005 to 0.1% by weight of oligopeptide A and from 0.00005 to 0.1% by weight of oligopeptide B.

In still further preferred uses of this latter embodiment the hair treatment agents - based on the weight of the composition - 0.0001 to 0.01 wt .-% oligopeptide A and 0.0001 to 0.001 wt .-% oligopeptide B.

 The oligopeptides used in the context of the present invention, which satisfy the abovementioned conditions, can advantageously be obtained from keratinic materials. It is preferred according to the invention that these oligopeptides are used in high proportions, based on the total keratinic peptide content of the agents. It is very particularly preferred that the highest possible proportion of all the keratinic peptides contained in the agent used according to the invention satisfies the conditions mentioned above.

 Preferred hair treatment agents used according to the invention are characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, more preferably at least 1% by weight, more preferably at least 2.5% by weight, still further preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Glu-Glu-Glu. Further preferred hair treatment agents used according to the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, more preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, still more preferably at least 5% by weight, and in particular at least 10% by weight, of all the keratinic peptides contained in the middle have the amino acid sequence Glu-Glu-Glu-Ile. Further preferred hair treatment agents used according to the invention are characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, more preferably at least 1% by weight, more preferably at least 2.5% by weight, even more preferably at least 5% by weight, and in particular at least 10% by weight, of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu. Particularly preferred hair treatment agents used according to the invention are characterized in that at least 0.1 wt .-%, preferably at least 0.5 wt .-%, more preferably at least 1 wt .-%, more preferably at least 2.5 wt .-%, still more preferably at least 5% by weight and in particular at least 10% by weight of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile.

 Very particularly preferred hair treatment agents used according to the invention are characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, particularly preferably at least 1% by weight, more preferably at least 2.5% by weight, even more preferably at least 5% by weight, and in particular at least 10% by weight, of all the keratinic peptides contained in the composition have the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg.

Still further preferred hair treatment agents used according to the invention are characterized characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, more preferably at least 1% by weight, more preferably at least 2.5% by weight, even more preferably at least 5% by weight. % and in particular at least 10 wt .-% of all keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val.

 Particularly preferred hair treatment agents used according to the invention are characterized in that at least 0.1% by weight, preferably at least 0.5% by weight, more preferably at least 1% by weight, more preferably at least 2.5% by weight, still more preferably at least 5% by weight, and in particular at least 10% by weight, of all the keratinic peptides contained in the middle have the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val-Leu.

 The above conditions relate to the total content of the agents used according to the invention to peptides derived from keratinic materials. In addition to the oligopeptides of keratinic origin, of course, other peptides and / or protenihydrolysates can be used, for example from other native sources. For example, the additional use of wheat protein hydrolysates is preferred, see below. It has been found that the combination of two active substances in the hair treatment compositions used according to the invention can be successfully supplemented by a third active substance, whereby the promotion or enhancement of hair growth, the reduction of hair loss, the activation of the hair root cells, the activation of hair follicles and the thickening of the hair can be further enhanced.

Here certain extracts have proven to be the third active ingredient in a special way.

In preferred uses according to the invention, the hair treatment composition contains at least one extract of Pisum sativium.

 Preferred agents used according to the invention are characterized in that they contain - based on their weight - 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0, 1 to 3 wt .-% of at least one extract of Pisum sativium included.

 Preferred uses according to the invention are characterized in that the hair treatment agent - based on its weight - 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0, 1 contains up to 3 wt .-% of at least one extract of Pisum sativium.

 It has been found that the positive properties of the agents used according to the invention can be increased still further, in particular with regard to the positive effects on the hair roots and the inner structural strengthening of the keratin fibers, if the agents used according to the invention contain purine or purine derivatives.

Preferred uses according to the invention are characterized in that the Hair treatment agent - based on its weight - 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% purine and / or purine derivative (s) of the formula (I)

in which the radicals R ¹ , R ² and R ^{3 are} independently selected from -H, - OH, -NH 2, -SH and the radicals R ⁴ , R ⁵ and R ^{6 are} independently selected from -H, -CH 3 and -CH 2 -CH ₃ , with the following compounds being preferred:

Purine (R ¹ = R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H), adenine (R ¹ = NH ₂ , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H), guanine (R ¹ = OH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H), uric acid (R ¹ = R ² = R ³ = OH, R ⁴ = R ⁵ = R ⁶ = H ), Hypoxanthine (R ¹ = OH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H), 6-purinethiol (R ¹ = SH, R ² = R ³ = R = _R 5 _{= R} 6 _{= H)} 6-thioguanine (R ¹ = SH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H), xanthine (R ¹ = R ² = OH, R ³ = R ⁴ = R ⁵ = R ⁶ = H), caffeine (R ¹ = R ² = OH, R ³ = H, R ⁴ = R ⁵ = R ⁶ = CH ₃ ), theobromine (R ¹ = R ² = OH, R ³ = R ⁴ = H, R ⁵ = R ⁶ = H), theophylline (R ¹ = R ² = OH, R ³ = H, R ⁴ = CH ₃ , R ⁵ = CH ₃ , R ⁶ = H).

 Preferred agents used according to the invention contain purine and / or purine derivatives in narrower ranges. Cosmetic compositions preferably used according to the invention are characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight. and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s).

Depending on the desired application of the cosmetic agent may vary the nature and amount of purine derivative. Caffeine has proved particularly useful in hair cosmetic formulations, for example in shampoos and conditioners, preferably in amounts of from 0.005 to 0.25% by weight, more preferably from 0.01 to 0.1% by weight and in particular from 0.01 to 0.05 wt .-% (in each case based on the agent) can be used.

 Hair-treatment compositions preferably used according to the invention contain - in each case based on their weight

0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate; - 0.0002 to 5 wt .-%, preferably 0.0005 to 2.5 wt .-%, more preferably 0.00075 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-%, more preferably 0.002 to 0.25 wt .-% and in particular 0.005 to 0.1 wt .-% oligopeptide (s) having the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val wherein the amino groups are free or protonated and the Carboxy groups may be free or deprotonated,

 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0.1 wt .-% caffeine.

 Hair treatment agents used particularly preferably according to the invention contain - in each case based on their weight

 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate;

 - 0.0002 to 5 wt .-%, preferably 0.0005 to 2.5 wt .-%, more preferably 0.00075 to 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-%, more preferably 0.002 to 0.25 wt .-% and in particular 0.005 to 0, 1 wt .-% oligopeptide (s) having the amino acid sequence Tyr-Glu-Glu-Glu-Ile-Arg-Val wherein the amino groups are free or protonated and the Carboxy groups may be free or deprotonated,

 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0.1 to 3 wt .-% of at least one extract of Pisum sativium,

 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% caffeine.

The agents used in the invention may contain other active ingredients and adjuvants. These are described below.

 The agents used according to the invention preferably additionally comprise at least one emulsifier or a surfactant, surface-active substances being referred to as surfactants or as emulsifiers, depending on the field of use, and selected from anionic, cationic, zwitterionic, ampholytic and nonionic surfactants and emulsifiers.

Preferred uses according to the invention are characterized in that the hair treatment agent - based on its weight - 0.5 to 70 wt .-%, preferably 1 to 60 wt .-%, more preferably 2.5 to 35 wt .-% and in particular 5 to 25% by weight of anionic and / or nonionic and / or cationic and / or amphoteric surfactant (s). Suitable anionic surfactants and emulsifiers for the compositions used according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. Example, a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule. Examples of suitable anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and ammonium as well as mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,

 linear and branched fatty acids with 8 to 30 carbon atoms (soaps),

Ethercarbonsäuren the formula R-0- (CH ₂ -CH ₂ 0) x-CH ₂ -COOH, in which R is a linear alkyl group having 8 to 30 carbon atoms and x = 0 or 1 to 16,

 Acylsarcosides having 8 to 24 carbon atoms in the acyl group,

 Acyltaurides having 8 to 24 carbon atoms in the acyl group,

 Acyl isethionates having 8 to 24 carbon atoms in the acyl group,

 linear alkanesulfonates having 8 to 24 C atoms,

 linear alpha-olefin sulfonates having 8 to 24 C atoms,

 Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 carbon atoms,

 Acylglutamates of the formula (T-1),

 XOOC-CH2CH2CH-COOX (T-1)

 I

HN-COR ¹

in which R ¹ CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which are derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as, for example, C 12/14 or C 12/18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, in particular sodium N-cocoyl and sodium N-stearoyl-L-glutamate,

Esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula ( ^" T1 ^" ),

X

I

HOCCOOR ¹ (T-II)

 I

Y-CH-COOR ² wherein X = H or a -ChbCOOR group, Y = H or -OH is under the condition that Y = H when X is -CH 2 COOR, R, R ¹ and R ^{2 are} independently a hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C6-Ci ₈ ) -alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C 6 -C 16) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals are selected, provided that at least one of the groups R, R ¹ or R ^{2 is} a radical Z,

 Esters of sulfosuccinic acid or sulfosuccinates of the general formula (TT-III),

in der M'^{n+ n)} für n = 1 ein Wasserstoffatom, ein Alkalimetallkation, eine Ammoniumgruppe oder das Kation einer ammonium-organischen Base und für n = 2 ein Erdalkalimetallkation darstellt und R¹ und R² unabhängig voneinander ein Wasserstoffatom, ein Alkali- oder Erdalkalimetallkation, eine Ammoniumgruppe, das Kation einer ammonium-organischen Base oder einen Rest Z bedeuten, der von einer polyhydroxylierten organischen Verbindung stammt, die aus der Gruppe der veretherten (C6-Ci8)-Alkylpolysaccharide mit 1 bis 6 monomeren Saccharideinheiten und/oder der veretherten aliphatischen (C6-Ci6)-Hydro- xyalkylpolyole mit 2 bis 16 Hydroxylresten ausgewählt ist, unter der Maßgabe, dass wenigstens eine der Gruppen R¹ oder R² ein Rest Z ist, H ₂ C COOR ¹ (T-III)

in M ' ^{n + n)} for n = 1 represents a hydrogen atom, an alkali metal cation, an ammonium group or the cation of an ammonium organic base and for n = 2 an alkaline earth metal cation and R ¹ and R ² independently represent a hydrogen atom, an alkali metal or Alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C6-Ci8) alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or the etherified aliphatic (C 6 -C 16) -hydroxyalkyl polyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R ¹ or R ^{2 is} a radical Z,

 Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,

- alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH ₂ -CH ₂ ) x-OSO ₃ H, in which R is a preferably linear alkyl group having 8 to 30 carbon atoms and x = 0 or 1-12, esters of tartaric acid and Citric acid with alcohols which are adducts of about 2-15 molecules of ethylene oxide and / or propylene oxide onto C8-22 fatty alcohols, alkyl and / or alkenyl ether phosphates,

 sulfated fatty acid alkylene glycol esters,

 Monoglyceride sulfates and monoglyceride ether sulfates.

Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which are particularly preferred Embodiments of an octanoyl, decanoyl, lauroyl, myristoyl, palmitoyl and stearoyl radical is selected, esters of tartaric acid, citric acid or succinic acid or the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-Glucoside Sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids containing 8 to 18 carbon atoms in the alkyl group and up to 12 ethoxy groups in the molecule, sulfonated succinic acid mono- and dialkyl esters of 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 18 C atoms in the alkyl group and 1 to 6 ethoxy groups.

Zwitterionic surfactants and emulsifiers are those surface-active compounds which carry in the molecule at least one quaternary ammonium group and at least one -COO ^(_) or -SO 3 ^H group. Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-Ν, Ν-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl 3-carboxymethyl-3-hydroxyethylimidazolines having in each case 8 to 18 carbon atoms in the alkyl or acyl group, and also the cocoacylaminoethylhydroxyethylcarboxymethylglycinate. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Ampholytic surfactants and emulsifiers are understood as meaning those surface-active compounds which, apart from a Ca-C2-alkyl or -acyl group, contain at least one free amino group and at least one -COOH or -SOsH group and are capable of forming internal salts. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and C12-C18 acylsarcosine.

Nonionic surfactants and emulsifiers contain as hydrophilic group z. For example, a polyol group, a polyalkylene glycol ether group or a combination of polyol and polyglycol ether group.

 Preferred nonionic surface-active substances are the alkylpolyglycosides, optionally mixed with fatty alcohols, alkoxylated polydialkylsiloxanes, alkylene oxide addition products of saturated linear fatty alcohols and fatty acids with in each case 2 to 30 moles of ethylene oxide per mole of fatty alcohol or fatty acid.

Also usable according to the invention are cationic surfactants of the quaternary ammonium compound type, the esterquats and the amidoamines. Preferred quaternary Ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides. The long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as. In cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride. Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.

 Very particularly preferred agents used according to the invention additionally comprise fatty alcohol (s) and / or fatty alcohol alkoxylate (s), preferably C 12-22 fatty alcohol (s) and / or C 12-22 fatty alcohol ethoxylate (s) with 10 to 30 EO units, especially preferably C16-18 fatty alcohol (s) and / or Ci6-ie fatty alcohol ethoxylate (s) having 12 to 20 EO units, preferably in amounts of 5 to 20 wt .-%, preferably from 7.5 to 17.5 wt .-% and in particular from 10 to 15 wt .-%, each based on the weight of the composition.

In summary, hair treatment agents used according to the invention are preferred, which - based on their weight - 0.1 to 20 wt .-%, preferably 0.25 to 17.5 wt .-% and in particular 5 to 15 wt .-% anionic (s) surfactant (E), particularly preferably Fettal kholethersulfate the formula

H ₃ C- (CH 2) n (OCH ₂ CH 2) k-OS03- M ⁺

in which n represents values of from 5 to 21, preferably from 7 to 19, particularly preferably from 9 to 17 and in particular from 1 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2 or 3 and especially 2, and M is a cation from the group Na ⁺ , K ⁺ NH ₄ ⁺ , Vz Mg ²⁺ , ¹ / Zn ²⁺ , preferably Na ⁺ , stand.

 Preferred hair-treatment agents used according to the invention are further characterized in that they additionally contain amphoteric surfactant (s), preferably from the groups of

N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkylimidodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids having in each case about 8 to 24 C atoms in the alkyl group, Alkylaminoacetic acids having in each case about 8 to 24 carbon atoms in the alkyl group, N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate, C 12 -C 18 -acylsarcosine, N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl -N, N-dimethylammonium glycinates, for example Kokosacylaminopropyl- dimethylammoniumglycinat, 2-alkyl-3-carboxymethyl-3-hydroxyethyl imidazoline having in each case 8 to 18 carbon atoms in the alkyl or acyl group, cocoacylaminoethylhydroxyethylcarboxymethylglycinat, the INCI name Cocamidopropyl betaine known compounds known under the INCI name Disodium Cocoamphodiacetate Compounds containing, preferred means according to the invention the amphoteric surfactant (s) in amounts of 1 to 15 wt .-%, preferably from 2.5 to 12% by weight and in particular from 5 to 10 wt .-%, each based on the total agent included. As a further optional component, the agents used according to the invention may contain from 0.01 to 10% by weight of at least one polymer from the group of cationic and / or amphoteric polymers.

 Cationic or amphoteric polymers are to be understood as meaning polymers which have a group in the main and / or side chain which may be "temporary" or "permanent" cationic. According to the invention, "permanently cationic" refers to those polymers which have a cationic group, irrespective of the pH of the agent. These are usually polymers containing a quaternary nitrogen atom, for example in the form of an ammonium group. Preferred cationic groups are quaternary ammonium groups. In particular, those polymers in which the quaternary ammonium group is bonded via a C 1-4 hydrocarbon group to a polymer main chain constructed from acrylic acid, methacrylic acid or derivatives thereof have proven to be particularly suitable.

 In addition to cationic polymers or in their place, the agents used in the invention may also contain amphoteric polymers. These additionally have at least one negatively charged group in the molecule and are also referred to as zwitterionic polymers.

 Preferably, the polymer or polymers are used within narrower ranges. Thus, agents used according to the invention are preferred which, based on their weight, contain 0.05 to 7.5% by weight, preferably 0.1 to 5% by weight, particularly preferably 0.2 to 3.5% by weight. and in particular from 0.25 to 2.5% by weight of amphoteric polymer (s).

 Regardless of whether amphoteric polymers are or are not included in the compositions, further preferred agents used according to the invention are characterized in that they contain, based on their weight, from 0.05 to 7.5% by weight, preferably from 0.1 to 5% by weight .-%, particularly preferably 0.2 to 3.5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) polymer (s) included.

Cationic polymers which can preferably be used according to the invention are described below: Homopolymers of the general formula (G1-I),

R ¹

- [CH ₂ -C-] _n (G1-I)

CO-O- (CH ₂ ) _m -N ⁺ R ² R ³ R ⁴ in which R ^{1 is} -H or -CH ³ , R ² , R ³ and R ^{4 are} independently selected from C 1-4 -alkyl, Alkenyl or hydroxyalkyl groups, m = 1, 2, 3 or 4, n is a natural number and X ^"is a physiologically acceptable organic or inorganic anion, as well as copolymers consisting essentially of the monomer units listed in formula (G1-I) and nonionic monomer units, are particularly preferred cationic polymers. Within the scope of these polymers, preference is given to those according to the invention for which at least one of the following conditions applies:

R ¹ is a methyl group

R ² , R ³ and R ⁴ are methyl groups

 m has the value 2.

Suitable physiologically tolerated counterions X ^" are, for example, halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ions.Holyidene ions, in particular chloride, are particularly suitable A particularly suitable homopolymer is the, if desired crosslinked, poly (methacryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium-37. such products are, for example, under the names Rheocare ^® CTH (Cosmetic Rheologies) and Synthalen® ^® CR (Ethnichem) commercially available. the crosslinking can, if desired, with the help of olefinically polyunsaturated compounds, for example divinylbenzene , Tetraallyloxyethane, methylenebisacrylamide, diallyl ether, polyallylpolyglyceryl ethers, or allyl ethers of sugars or sugar derivatives such as erythritol, pentaerythritol, arabitol, mannitol, sorbitol, sucrose or glucose methylenebisacrylamide is a preferred crosslinking site ns.

The homopolymer is preferably used in the form of a nonaqueous polymer dispersion which should not have a polymer content of less than 30% by weight. Such polymer dispersions are (under the names Salcare ^® SC 95 about 50% polymer content, additional components: mineral oil (INCI name: Mineral Oil) and tridecyl polyoxypropylene polyoxyethylene ether (INCI name: PPG-1 trideceth-6) ) and Salcare ^® SC 96 (about 50% polymer content, additional components: mixture of diesters of propylene glycol (with a mixture of caprylic and capric acid INCI name: propylene glycol Dicaprylate / Dicaprate) and tridecyl-polyoxypropylene-polyoxyethylene ether (INCI name: PPG-1 -Trideceth-6)) are commercially available.

Copolymers with monomer units of the formula (G1 -I) contain as nonionic monomer units preferably acrylamide, methacrylamide, acrylic acid C-alkyl esters and methacrylic acid C 1-4 -alkyl esters. Among these nonionic monomers, the acrylamide is particularly preferred. These copolymers can also be crosslinked, as described above in the case of the homopolymers. A copolymer preferred according to the invention is the crosslinked acrylamide-methacryloyloxyethyltrimethylammonium chloride copolymer. Such copolymers in which the monomers are present in a weight ratio of about 20:80, are commercially available as approximately 50% non-aqueous polymer dispersion 92 under the name Salcare ^® SC.

It is likewise possible to use the polymers known under the names Polyquaternium-24 (commercial product eg Quatrisoft® LM 200) as cationic polymers. Also suitable for use in accordance with the invention are the copolymers of vinylpyrrolidone, such as the commercial products Copolymer 845 (manufacturer: ISP), Gaffix® VC 713 (manufacturer: ISP), Gafquat®ASCP 101 1, Gafquat®HS 1 10, Luviquat® 8155 and Luviquat® MS 370 are available. Cationic protein hydrolysates may also be used as cationic polymers, preferred agents being one or more cationic protein hydrolyzates from the group Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Hydroxypropyl Arginine Lauryl / Myristyl Ether HCl, Hydroxypropyltrimonium Gelatin, Hydroxypropyltrimonium Hydrolyzed Casein, Hydroxypropyltrimonium Hydrolyzed Collagen, Hydroxypropyltrimonium Hydrolyzed Conchiolin Protein, Hydroxypropyltrimonium Hydrolyzed Keratin, Hydroxypropyltrimonium Hydrolyzed Rice Bran Protein, Hydroxypropyltrimonium Hydrolyzed Soy Protein, Hydroxypropyl Hydrolyzed Vegetable Protein, Hydroxypropyltrimon Hydroxylzed Wheat Protein, Hydroxypropyltrimonium Hydrolyzed Wheat Protein / Siloxysilicate, Lauridimonium Hydroxypropyl Hydrolyzed Soy Protein, Lauridimonium Hydroxypropyl Hydrolyzed Wheat Protein, Laurodimonium Hydroxypropyl Hydrolyzed Wheat Protein / Siloxysilicate, Lauryldimonium Hydroxypropyl Hydrolyzed Casein, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen, Lauryldimonium Hydroxypropyl Hydrolyzed Keratin, Lauryldimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Casein, Steardimonium Hydroxypropyl Hydrolyzed Collagen, Steardimonium Hydroxypropyl Hydrolyzed Keratin, Steardimonium Hydroxypropyl Hydrolyzed Rice Protein, Steardimonium Hydroxypropyl Hydrolyzed Soy Protein, Steardimonium Hydroxypropyl Hydrolyzed Vegetable Protein, Steardimonium Hydroxypropyl Hydrolyzed Wheat Protein, Steartrimonium Hydroxyethyl Hydrolyzed Collagen, Quaternium-76 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Collagen, Quaternium-79 Hydrolyzed Keratin, Quaternium-79 Hydrolyzed Milk Protein, Quaternium-79 Hydrolyzed Soy Protein, Quaternium-79 Hydrolyzed Wheat Protein included.

 In summary, uses according to the invention are preferred in which the hair treatment composition - based on its weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3.5 wt. % and in particular 0.25 to 2.5% by weight of cationic polymer (s), with preferred cationic polymer (s) being / are selected from poly (methacryloyloxyethyltrimethylammonium chloride) (INCI: Polyquaternium) 37) and / or quaternized cellulose derivatives (INCI: Polyquaternium 10) and / or cationic alkylpolyglycosides and / or cationised honey and / or cationic guar derivatives and / or polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or copolymers of vinylpyrrolidone with quaternized derivatives of Diaikyiaminoalkyiacryiats and -methacrylate and / or vinylpyrrolidone-Vinylimidazoliummethochlorid copolymers and / or quaternized polyvinyl alcohol and / or Polyquaternium 2 and / or Polyquaternium-7 and / or Polyquaternium 17 and / or Polyquaternium 18 and / or Polyquaternium 24 and / or Polyquaternium 27.

 In addition to or in place of the cationic polymers, the agents used in the invention may contain amphoteric polymers. In the context of the present invention preferably usable amphoteric polymers are composed essentially together

A) monomers having quaternary ammonium groups of the general formula (Z-1),

R ¹ -CH = CR ² -CO-Z- (C _n H _2n ) -N ( ⁺ ) R ³ R ⁴ R ⁵ A <^" ) <^Z"')

In the R and R ^{2 are} independently of each other hydrogen or a methyl group and R ³ , R ⁴ and R ^ independently represent alkyl groups having 1 to 4 carbon atoms, Z is an NH group or an oxygen atom, n is an integer of 2 to 5 and

A <-> is the anion of an organic or inorganic acid and

 B) monomeric carboxylic acids of the general formula (Z-1 I),

R ⁶ -CH = CR ⁷ -COOH (Z-II)

in which R ⁶ and fiJ are independently hydrogen or

Are methyl groups. Suitable starting monomers are, for. Dimethylaminoethylacrylamide, dimethylaminoethylmethacrylamide, dimethylaminopropylacrylamide, dimethylaminopropylmethacrylamide and diethylaminoethylacrylamide when Z is an NH group or dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate and diethylaminoethyl acrylate when Z is an oxygen atom.

 The monomers containing a tertiary amino group are then quaternized in a known manner, methyl chloride, dimethyl sulfate or diethyl sulfate being particularly suitable as alkylating reagents. The quaternization reaction can be carried out in aqueous solution or in the solvent.

Advantageously, those monomers of formula (ZI) which are derivatives of acrylamide or methacrylamide. Preference is furthermore given to those monomers which contain halide, methoxysulfate or ethoxysulfate ions as counterions. Also preferred are those monomers of formula (ZI) wherein R 1, R ⁴ and R ^{5 are} methyl groups. The acrylamidopropyltrimethylammonium chloride is a very particularly preferred monomer of the formula (ZI).

 Suitable monomeric carboxylic acids of the formula (Z-I) are acrylic acid, methacrylic acid, crotonic acid and 2-methylcrotonic acid. Preference is given to using acrylic or methacrylic acid, in particular acrylic acid.

 The zwitterionic polymers which can be used according to the invention are prepared from monomers of the formulas (Z-1) and (Z-II) by polymerization processes known per se. The polymerization can be carried out either in aqueous or aqueous-alcoholic solution. The alcohols used are alcohols having 1 to 4 carbon atoms, preferably isopropanol, which simultaneously serve as polymerization regulators. However, other components than regulators may also be added to the monomer solution, eg. For example, formic acid or mercaptans, such as thioethanol and thioglycolic acid. The initiation of the polymerization takes place with the aid of free-radical-forming substances. For this purpose, redox systems and / or thermally decomposing radical formers of the azo compound type, such. As azoisobutyronitrile, azo-bis (cyanopentanoic acid) or azo-bis (amidinopropane) dihydrochloride can be used. As redox systems are z. B. combinations of hydrogen peroxide, potassium or ammonium peroxodisulfate and tertiary butyl hydroperoxide with sodium sulfite, sodium dithionite or hydroxylamine hydrochloride as a reduction component.

The polymerization can be carried out isothermally or under adiabatic conditions, depending on the concentration ratios by the heat of polymerization released, the temperature range for the course of the reaction between 20 and 200 ° C may vary, and the reaction may be carried out under the autogenous pressure. Preferably, the reaction temperature is between 20 and 100 ° C. The pH during the copolymerization may vary within a wide range. Advantageously, polymerization is carried out at low pH values; however, pH values above the neutral point are also possible. After the polymerization is treated with an aqueous base, for. As sodium hydroxide, potassium hydroxide or ammonia, to a pH between 5 and 10, preferably 6 to 8 set. Further details of the polymerization process can be found in the examples.

 Be particularly effective, such polymers have proven in which the monomers of the formula (Z-l) were present in excess over the monomers of formula (Z-II). It is therefore preferred in accordance with the invention to use those polymers which consist of monomers of the formula (Z1) and the monomers of the formula (Z-II) in a molar ratio of 60:40 to 95: 5, in particular 75:25 to 95: 5 , consist.

 Preferred agents to be used according to the invention are characterized in that the amphoteric polymer (s) comprises monomers A) and B), wherein A) and B) are selected from

 A) monomers having quaternary ammonium groups of the general formula (Z-1),

R ¹ -CH = CR ² -CO-Z- (C _n H _2n ) -N ( ⁺ ) R ³ R ⁴ R ⁵ A ^ ( ^Z_l )

in which R and R ² independently represent hydrogen or a

Methyl group and R ³ , R ⁴ and R ^{5 are} independently alkyl groups having 1 to 4 carbon atoms, Z is an NH group or an oxygen atom, n is an integer from 2 to 5 and A (-) the anion of an organic or inorganic Acid is

 and

 B) monomeric carboxylic acids of the general formula (Z-II),

R ⁶ -CH = CR ⁷ -COOH (Z-II)

in which R ⁶ and R ^{7 are} independently hydrogen or methyl groups.

 With particular preference, the amphoteric polymers used in the compositions according to the invention contain monomers from the group of acrylamides and / or methacrylamides with alkylammonium groups. Acrylic acid and / or methacrylic acid and / or crotonic acid and / or 2-methyl-crotonic acid have proven useful as monomers with anionic groups which are additionally present in the polymers.

In summary, agents used according to the invention are preferred in which the amphoteric polymer (s) are copolymers of at least one of the monomers trimethylammoniumethylacrylamide and / or trimethylammoniumethylmethacrylamide and / or trimethylammoniumpropylacrylamide and / or trimethylammonium propylmethacrylamide and / or trimethylammoniumethylacrylamide and / or trimethylammoniumethylacrylate and / or trimethylammoniumethylmethacrylate and / or trimethylammoniumethylacrylate and / or ethyldimethylammoniumethylacrylamide and / or ethyldimethylammoniumethylmethacrylamide and / or ethyldimethylammoniumpropylacrylamide and / or ethyldimethylammoniumpropylmethacrylamide and / or ethyldimethylammoniumethylacrylamide and / or ethyldimethylammoniumethylacrylate and / or ethyldimethylammoniumethylmethacrylate and / or Ethyldimethyl- ammonium ethyl acrylate with at least one of the monomers acrylic acid and / or methacrylic acid and / or crotonic acid and / or 2-methyl crotonic acid.

Particularly preferred amphoteric polymers according to the invention are:

 Copolymers of trimethylammonium ethylacrylamide with acrylic acid

 Copolymers of methyl thylammonium ethylacrylamide with methacrylic acid

 Copolymers of trimethylammonium ethylacrylamide with crotonic acid

 Copolymers of trimethylammonium ethylacrylamide with 2-methyl-crotonic acid

 Copolymers of trimethylammonium ethylmethacrylamide with acrylic acid

 Copolymers of trimethylammonium ethylmethacrylamide with methacrylic acid

 Copolymers of trimethylammonium ethylmethacrylamide with crotonic acid

 Copolymers of trimethylammonium ethylmethacrylamide with 2-methyl-crotonic acid

Copolymers of trimethylammonium propylacrylamide with acrylic acid

 Copolymers of methyl thylammoniumpropylacrylamide with methacrylic acid

 Copolymers of trimethylammonium propylacrylamide with crotonic acid

 Copolymers of trimethylammonium propylacrylamide with 2-methylcrotonic acid

Copolymers of trimethylammonium propylmethacrylamide with acrylic acid

 Copolymers of methyl ammonium propyl methacrylamide with methacrylic acid

 Copolymers of trimethylammopropylpropylmethacrylamide with crotonic acid

 Copolymers of trimethylammopropylpropylmethacrylamide with 2-methyl-crotonic acid

Copolymers of trimethylammonium ethylacrylamide with acrylic acid

 Copolymers of methyl thylammonium ethylacrylamide with methacrylic acid

 Copolymers of trimethylammonium ethylacrylamide with crotonic acid

 Copolymers of trimethylammonium ethylacrylamide with 2-methyl-crotonic acid

 Copolymers of methyl methacrylate with acrylic acid

 Copolymers of methyl methacrylate with methacrylic acid

 Copolymers of trimethyl ammonium ethyl acrylate with crotonic acid

 Copolymers of tr methyl ammonium ethyl acrylate with 2-methyl crotonic acid

 Copolymers of trimethylammonium ethyl methacrylate with acrylic acid

 Copolymers of methyl methacrylate with methacrylic acid

Copolymers of methyl methacrylate with crotonic acid Copolymers of trimethylammoniumethyl methacrylate with 2-methyl-crotonic acid copolymers of trimethylammonium ethyl acrylate with acrylic acid

Copolymers of trimethylammonium ethyl acrylate with methacrylic acid

Copolymers of trimethylammonium ethyl acrylate with crotonic acid

Copolymers of trimethylammonium ethyl acrylate with 2-methyl-crotonic acid

Copolymers of ethyldimethylammoniumethylacrylamide with acrylic acid

Copolymers of ethyldimethylammoniumethylacrylamide with methacrylic acid

Copolymers of ethyldimethylammoniumethylacrylamide with crotonic acid

Copolymers of ethyldimethylammoniumethylacrylamide with 2-methyl-crotonic acid Copolymers of ethyldimethylammoniumethylmethacrylamide with acrylic acid

Copolymers of ethyldimethylammoniumethylmethacrylamide with methacrylic acid Copolymers of ethyldimethylammoniumethylmethacrylamide with crotonic acid Copolymers of ethyldimethylammoniumethylmethacrylamide with 2-methylcrotonic acid Copolymers of ethyldimethylammoniumpropylacrylamide with acrylic acid

Copolymers of ethyldimethylammoniumpropylacrylamide with methacrylic acid

Copolymers of ethyldimethylammoniumpropylacrylamide with crotonic acid

Copolymers of ethyldimethylammoniumpropylacrylamide with 2-methyl-crotonic acid Copolymers of ethyldimethylammoniumpropylmethacrylamide with acrylic acid Copolymers of ethyldimethylammoniumpropylmethacrylamide with methacrylic acid Copolymers of ethyldimethylammoniumpropylmethacrylamide with crotonic acid Copolymers of ethyldimethylammoniumpropylmethacrylamide with 2-methylcrotonic acid

 Copolymers of ethyldimethylammoniumethylacrylamide with acrylic acid

Copolymers of ethyldimethylammoniumethylacrylamide with methacrylic acid

Copolymers of ethyldimethylammoniumethylacrylamide with crotonic acid

Copolymers of ethyldimethylammoniumethylacrylamide with 2-methyl-crotonic acid Copolymers of ethyldimethylammonium ethylacrylate with acrylic acid

Copolymers of ethyldimethylammonium ethyl acrylate with methacrylic acid

Copolymers of ethyldimethylammonium ethyl acrylate with crotonic acid

Copolymers of ethyldimethylammonium ethylacrylate with 2-methyl-crotonic acid Copolymers of ethyldimethylammoniumethylmethacrylate with acrylic acid

Copolymers of ethyldimethylammonium ethyl methacrylate with methacrylic acid

Copolymers of ethyldimethylammonium ethyl methacrylate with crotonic acid

Copolymers of ethyldimethylammoniumethyl methacrylate with 2-methylcrotonic acid Copolymers of ethyldimethylammonium ethylacrylate with acrylic acid

Copolymers of ethyldimethylammonium ethyl acrylate with methacrylic acid

Copolymers of ethyldimethylammonium ethyl acrylate with crotonic acid Copolymers of ethyldimethylammonium ethyl acrylate with 2-methyl-crotonic acid The agents used according to the invention may furthermore contain all active ingredients, additives and auxiliaries known for such preparations. In many cases, the agents contain at least one surfactant, with both anionic and zwitterionic, ampholytic, nonionic and cationic surfactants being suitable in principle. In many cases, however, it has proved to be advantageous to select the surfactants from anionic, zwitterionic or nonionic surfactants. These surfactants have been described in detail above.

 Finally, the compositions used according to the invention may also contain plant extracts (L).

 Usually these extracts are produced by extraction of the whole plant. However, in individual cases it may also be preferred to prepare the extracts exclusively from flowers and / or leaves of the plant.

 The extracts of green tea, oak bark, stinging nettle, witch hazel, hops, henna, chamomile, burdock root, horsetail, hawthorn, linden, almond, aloe vera, spruce needle, horse chestnut, sandalwood, juniper, coconut, mango, apricot, lime , Wheat, kiwi, melon, orange, grapefruit, sage, rosemary, birch, mallow, meadowfoam, quenelle, yarrow, thyme, lemon balm, toadstool, coltsfoot, marshmallow, meristem, ginseng and ginger root.

 Particularly preferred are the extracts of green tea, oak bark, stinging nettle, witch hazel, hops, chamomile, burdock root, horsetail, lime blossom, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi, melon, orange, grapefruit, sage, Rosemary, birch, meadowfoam, quenelle, yarrow, toadstool, meristem, ginseng and ginger root.

 Especially suitable for the use according to the invention are the extracts of green tea, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi and melon.

 As extraction agent for the preparation of said plant extracts water, alcohols and mixtures thereof can be used. Among the alcohols are lower alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol and propylene glycol, both as sole extractant and in admixture with water, are preferred. Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.

The plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture. Furthermore, it may be preferable to use mixtures of several, in particular two, different plant extracts in the compositions used according to the invention.

In addition, it may prove advantageous if the agents used according to the invention contain penetration aids and / or swelling agents (M). These include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and derivatives thereof, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, hydroxides. gencarbonates, diols and triols, and in particular 1, 2-diols and 1, 3-diols such as 1, 2-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-dodecanediol, 1, 3-propanediol , 1, 6-hexanediol, 1, 5-pentanediol, 1, 4-butanediol.

 For aesthetic reasons, "clear" products are often preferred by consumers, hair treatment agents preferably used according to the invention are therefore transparent or translucent, transparent or translucent in the context of the present invention means a composition having an NTU value of less than 100. The NTU (Nephelometry Turbidity Unit) value is a fluid turbidity measurement unit used in water treatment and is the unit of turbidity of a fluid measured with a calibrated nephelometer.

Claims

claims:  1. Use of a hair treatment composition containing  c) at least one compound selected from L-carnitine and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl L-carnitine and L-carnitine tartrate;  d) at least one oligopeptide containing at least one amino acid sequence Glu-Glu-Glu

 wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated  to  Promotion or enhancement of hair growth and / or  Reduction of hair loss and / or  Activation of hair root cells and / or  Activation of hair follicles and / or  Thickening of the hair.  Use according to claim 1, characterized in that the hair treatment agent - based on its weight - 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0, 1 to 3 wt .-% of at least one compound selected from L-carnitine, and / or the carnitine derivatives acetyl-L-carnitine, L-carnitine fumarate, L-carnitine Citrate, lauroyl-L-camitine and especially L-camitine tartrate.  Use according to one of claims 1 or 2, characterized in that the hair treatment agent - based on its weight - 0.0002 to 5 wt .-%, preferably 0.0005 to 2.5 wt .-%, more preferably 0.00075 bis 1 wt .-%, particularly preferably 0.001 to 0.5 wt .-%, more preferably 0.002 to 0.25 wt .-% and in particular 0.005 to 0.1 wt .-% oligopetide (s) having at least one amino acid sequence Glu Glu-Glu included. Use according to one of Claims 1 to 3, characterized in that the oligopeptide comprises 5 to 15 amino acids, preferably 6 to 13 amino acids, more preferably 7 to 12 amino acids and in particular 8, 9 or 10 amino acids, and a molecular weight of 650 to 3000 Da, preferably from 750 to 2500 Da, more preferably from 850 to 2000 Da and in particular from 1000 to 1600 Da has.  Use according to one of Claims 1 to 4, characterized in that the oligopeptide has at least one amino acid sequence Tyr-Glu-Glu-Glu-Ile

 wherein the amino group may be free or protonated and the carboxy groups may be free or deprotonated.  Use according to one of Claims 1 to 5, characterized in that the oligopeptide has at least one amino acid sequence Tyr-Gl-Glu-Glu-Ile-Arg-Val-Leu

wherein the amino groups are free or protonated and the carboxy groups may be free or deprotonated,  7. Use according to one of claims 1 to 6, characterized in that the hair treatment agent - based on its weight - 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt. % and in particular 0, 1 to 3 wt .-% of at least one extract of Pisum sativium. 8. Use according to one of claims 1 to 7, characterized in that the hair treatment agent - based on its weight - 0.0005 to 7.5 wt .-%, preferably 0.001 to 6 wt .-%, more preferably 0.005 to 5 wt .-%, more preferably 0.01 to 4 wt .-% and in particular 0, 1 to 3 wt .-% purine and / or purine derivative (s) of the formula (I)

in which the radicals R ¹ , R ² and R ^{3 are} independently selected from -H, - OH, -NH 2, -SH and the radicals R ⁴ , R ⁵ and R ^{6 are} independently selected from -H, -CH 3 and -CH 2 -CH 3, the following compounds being preferred: Purine (R ¹ = R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) Adenine (R ¹ = NH ₂ , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) Guanine (R ¹ = OH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H) Uric acid (R ¹ = R ² = R ³ = OH, R ⁴ = R ⁵ = R ⁶ = H) Hypoxanthine (R ¹ = OH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) 6-purethiol (R ¹ = SH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H) 6-thioguanine (R ¹ = SH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H) Xanthine (R ¹ = R ² = OH, R ³ = R ⁴ = R ⁵ = R ⁶ = H) Caffeine (R ¹ = R ² = OH, R ³ = H, R ⁴ = R ⁵ = R ⁶ = CH ₃ ) - Theobromine (R ¹ = R ² = OH, R ³ = R ⁴ = H, R ⁵ = R ⁶ = H) Theophylline {R ¹ = R ² = OH, R ³ = H, R ⁴ = CH ₃ , R ⁵ = CH ₃ , R ⁶ = H).  9. Use according to one of claims 1 to 8, characterized in that the hair treatment agent - based on its weight - 0.5 to 70 wt .-%, preferably 1 to 60 wt .-%, more preferably 2.5 to 35 wt % and in particular 5 to 25% by weight of anionic and / or nonionic and / or cationic and / or amphoteric surfactant (s).  10. Use according to one of claims 1 to 9, characterized in that the hair treatment agent - based on its weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0, From 2 to 3.5% by weight, and more preferably from 0.25 to 2.5% by weight of cationic polymer (s), with preferred cationic polymer (s) being selected  Poly (methacryloyloxyethyltrimethylammonium chloride) (INCI: Polyquaternium-37) and / or;  quaternized cellulose derivatives (INCI: Polyquaternium 10) and / or cationic alkyl polyglycosides and / or  cationised honey and / or cationic guar derivatives and / or polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid and / or  Copolymers of vinylpyrrolidone with quaternized derivatives of dialkylaminoalkyl acrylate and methacrylate and / or  Vinylpyrrolidone-Vinylimidazoliummethochlorid copolymers and / or quaternized polyvinyl alcohol and / or  Polyquaternium 2 and / or  Polyquaternium-7 and / or  Polyquaternium 17 and / or  Polyquaternium 18 and / or  Polyquaternium 24 and / or  Polyquaternium 27.